

Indication	Sponsor Protocol Number NCT Number	Study Description	Investigator 24 Hour Contact Info	Study Coordinator Regular Business Hours Contact Info (Primary Coord. Listed First)	Sponsor Emergency Contact If local contacts are unavailable
Type 2 Diabetes	Eli Lilly 18F-MC-GPGM NCT03730662	Efficacy and Safety of LY3298176 Once Weekly versus Insulin Glargine in Patients with Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)	Michael Chen, MD 541-754-1150	Lisa Buchheit 541-754-1398, x3 Josh Borunda 541-754-1398, x6	317-655-7692
Cardiac Risk Reduction	Novo Nordisk EX9536-4388 NCT03574597	SELECT – Semaglutide effects on cardiovascular outcomes in people with overweight or obesity	Michael Chen, MD 541-754-1150	Kim Tally 541-754-1398, x8 Josh Borunda 541-754-1398, x6	609-987-5817 or 609-902-0903
Asthma No Active Treatment	AstraZeneca D3250R00023 NCT03373045	The CHRONICLE Study: A Longitudinal Prospective Observational Study of the characteristics, Treatment Patterns and health Outcomes of Individuals with Severe Asthma in the United States	Vincent Gimino, MD 541-754-1150	Carlene Chen 541-754-1398, x2 Josh Borunda 541-754-1398, x6	301-398-4454
Recurrent Vulvovaginal Yeast Infection No Active Treatment	Mycovia VMT-VT-1161-CL-011 NCT03562156	VIOLET - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VT-1161 Oral Capsules in the Treatment of Subjects with Recurrent Vulvovaginal Candidiasis	Ruth Palma, RP, FNP 541-754-1150	Julie Carrico 541-754-1398, x4 Josh Borunda 541-754-1398, x6	919-649-3920
Dust Mite Allergies	ALK MT-12 NCT04145219	A one-year placebo-controlled phase III trial evaluating the efficacy and safety of the house dust mite (HDM) SLIT-tablet in children (5-11 years of age) with HDM allergic rhinitis/rhinoconjunctivitis with or without asthma	Roland Solensky, MD	Lisa Buchheit 541-754-1398, x3 Josh Borunda 541-754-1398, x6	+45 2081 7724
Co-administration of Menveo and Bexsero Vaccines	GSK V72_79 NCT04318548	Safety and Immunogenicity Study of GSK Meningococcal Group B Vaccine <i>Bexsero</i> (GSK3536829A) when Administered Concomitantly with GSK Meningococcal MenACWY Conjugate Vaccine <i>Menveo</i> (GSK3536820A) to Healthy Subjects 16-18 Years of Age	Christy Rivers, DO	Julie Carrico 541-754-1398, x4 Josh Borunda 541-754-1398, x6	877-870-0019

Indication	Sponsor Protocol Number NCT Number	Study Description	Investigator 24 Hour Contact Info	Study Coordinator Regular Business Hours Contact Info (Primary Coord. Listed First)	Sponsor Emergency Contact If local contacts are unavailable
COVID Vaccine	Janssen Ensemble NCT04505722	A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COVID.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older	Michael Chen MD	Rich Tomasco 541-754-1398, x5 Josh Borunda 541-754-1398, x6	+1 (844) 551-8271